Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 3/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | MAPT | P10636 | 2/20 | 0.47 |
| ▸ | LMNA | P02545 | 2/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | ADH5 | P11766 | 3/20 | 0.46 |
| ▸ | SLC9A1 | P19634 | 1/20 | 0.40 |
| ▸ | F9 | P00740 | 1/20 | 0.38 |
| ▸ | F10 | P00742 | 1/20 | 0.38 |
| ▸ | ABL1 | P00519 | 1/20 | 0.37 |
| ▸ | BAZ2B | Q9UIF8 | 1/20 | 0.36 |
| ▸ | GPBAR1 | Q8TDU6 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7079970 | 0.82 | CYP1A2 (0.47) | CYP3A4CYP1A2CYP2C19ALDH1A1MAPT | |
| Hydrochloric Acid SCHEMBL7082587 | 0.81 | CYP1A2 (0.46) | CYP3A4CYP1A2CYP2C19ALDH1A1MAPT | |
| SCHEMBL3531980 | 0.80 | ADH5 (0.66) | CYP3A4CYP1A2CYP2C19ALDH1A1MAPT | |
| SCHEMBL3972148 | 0.79 | CYP1A2 (0.49) | CYP3A4CYP1A2CYP2C19ALDH1A1MAPT | |
| SCHEMBL3974651 | 0.75 | ALDH1A1 (0.44) | CYP3A4CYP1A2CYP2C19ALDH1A1MAPT | |
| Hydrochloric Acid SCHEMBL3971651 | 0.74 | ALDH1A1 (0.43) | CYP3A4CYP1A2CYP2C19ALDH1A1MAPT | |
| SCHEMBL3976725 | 0.73 | HDAC8 (0.47) | GPBAR1 | |
| SCHEMBL994454 | 0.72 | CYP1A2 (0.62) | CYP3A4CYP1A2CYP2C19ALDH1A1MAPT | |
| SCHEMBL3974655 | 0.70 | SLC9A1 (0.44) | CYP3A4CYP1A2CYP2C19ALDH1A1MAPT | |
| Hydrochloric Acid SCHEMBL6837522 | 0.70 | SLC9A1 (0.44) | CYP3A4CYP1A2CYP2C19ALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0921117-B2 | Acylguanidines | SANOFI AVENTIS DEUTSCHLAND (DE) | 2009-01-07 | — | — | EP | disclosed |
| US-20040044081-A1 | Diacyl-substituted guanidines, a process for their preparation, their use as medicament or diagnostic aid, and medicament containing them | HOECHST AKTIENGESELLSCHAFT | 2004-03-04 | — | — | US | disclosed |
| EP-0921117-B1 | Acylguanidines | AVENTIS PHARMA GMBH (DE) | 2003-12-10 | — | — | EP | disclosed |
| US-6632840-B1 | Inhibiting the Na+/H+ exchanger, treating at least one of arrhythmias and shock | HOECHST AKTIENGESELLSCHAFT (DE) | 2003-10-14 | — | — | US | disclosed |
| US-6436999-B1 | REACTING GUANIDINE AND CARBOCYCLIC ACIDS, TO FORM COMPOUNDS LIKE BIS(3-METHYLSULFONYL-4-I-PROPYLBENZOYL)GUANIDINE, USED FOR PROPHYLAXIS OF CARDIOVASCULAR DISORDERS AND AS PRODRUGS FOR SODIUM CHANNEL MODULATORS TO CONTROL BLOOD PRESSURE | HOECHST AKTIENGESELLSCHAFT (DE) | 2002-08-20 | — | — | US | disclosed |
| EP-0640587-B1 | Diacyl substituted guanidins, process for their preparation, their use as medicament or diagnostic reagent and medicament containing them | HOECHST AG (DE) | 1999-12-29 | — | — | EP | disclosed |
| EP-0921117-A2 | Acylguanidines | HOECHST AKTIENGESELLSCHAFT (DE) | 1999-06-09 | — | — | EP | disclosed |
| EP-0640587-A1 | Diacyl substituted guanidins, process for their preparation, their use as medicament or diagnostic reagent and medicament containing them | HOECHST AKTIENGESELLSCHAFT (DE) | 1995-03-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040044081-A1 | Diacyl-substituted guanidines, a process for their preparation, their use as medicament or diagnostic aid, and medicament containing them | ADRA1B, ADRA1A, HYOU1 | CYP3A4 2440/4885CYP1A2 581/4885CYP2C19 2852/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.